The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
Cipla gets EIR from USFDA for Kurkumbh facility
More from Industry NewsMore posts in Industry News »
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference
- India initiates antidumping probe on certain type of steel from Brazil, China, Germany
- BDR Pharma receives DGCI nod for its generic drug BIAPENEM
- AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs